Menlo Therapeutics Inc.

Cetus Corporation

Panorama Research Inc.

Braasch Biotech LLC

Larix Bioscience LLC

Neuromolecular, Inc.

Other

Leland Stanford Junior University

Tigercat Pharma, Inc.

Chiron Corporation

Celonova Biosciences, Inc.

University of California

Adamas Pharmaceuticals, Inc.

Vyne Therapeutics Inc.

Transtarget, Inc.

James W Larrick

Xiaoming Zhang

Edward F Schnipper

Andrew J Perlman

Yuqiang Wang

Bo Yu

Susan C Wright

Keith N Haffer

Andrew R Mendelsohn

Stuart A Lipton

Andrew A Raubitschek

Andrew R Raubitschek

Wenqing Ye

Jonathan S Stemler

James Clayton Peacock, Iii

Cyrus K Becker

Edgar George Engleman

Meenakshi S Venkatraman

Peter Ralph

George A Martin

Peng Yi

Pei Yu

Zaijun Zhang

Yewei Sun

Gaoxiao Zhang

Steven K Foung

Michael Piatak

Luchen Shan

Zheng Liu

Kenneth E Truitt

Andrew Mendelsohn

David F Mark

Randall J Lee

Leo S Lin

L L Houston

John C Cambier

Naomi Balaban

Gordon M Ringold

John M Wages

Manley Huang

F Carl Grumet

Michimasa Hirata

Shirley Sulastri Mihardja

George Senyk

Vikram Sharma

Fu-chu He

Chu-tse Wu

Qiang Tu

Eric S Groves

Frank M Torti

Stuart Arthur Lipton

Keith Lynn Wycoff

Keith L Wycoff

Lloyd M Yu

The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.

Aminoadamantyl nitrate compounds and their use to treat CNS disorders

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II).  The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

Amantadine nitrate compounds for use as medicaments for the treatment of diseases

The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.

Anti-CD79 antibodies and their uses

The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.

Methods and compositions for producing double allele knock outs

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

Use of NK-1 receptor antagonist serlopitant in pruritus

The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.

Cell line screening method

Use of NK-1 receptor antagonists in pruritus

The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.

Anti-marinobufagenin antibodies and uses thereof

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof

Growing community of inventors

Mountain View, CA, United States of America

James W Larrick